AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

-Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period (at least 10 weeks after study intervention).

* Known immunization or hypersensitivity to any botulinum neurotoxin serotype * Any medical condition that may put the participant at increased risk with exposure to AGN-151586, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function * Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or the inability to substantially lessen facial lines even by physically spreading them apart, as determined by the investigator * Any brow or eyelid ptosis, as determined by the investigator * Infection or skin disorder at the injection sites * History of facial nerve palsy * Any uncontrolled systemic disease * Anticipated need for treatment with botulinum neurotoxin of any serotype for any reason during the study (other than study intervention) * Anticipated need for surgery or overnight hospitalization during the study * Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow lift, or related procedures (eg, eyelid \[blepharoplasty\] and/or eyebrow surgery) * Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg, Gore-Tex®), and/or autologous fat transplantation * Current enrollment in an investigational drug or device study or participation in such a study within 30 days of Screening